Minerva Neurosciences Announces Proposed Public Offering of Common Stock
(Thomson Reuters ONE) -
WALTHAM, Mass., June 13, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc.
(NASDAQ:NERV), a clinical-stage biopharmaceutical company, today announced its
intention to offer and sell shares of its common stock in an underwritten public
offering pursuant to an existing shelf registration statement. All of the shares
in the proposed offering are to be sold by Minerva. The offering is subject to
market conditions, and there can be no assurance as to whether or when the
offering may be completed, or the actual size or terms of the offering.
Jefferies LLC is acting as the sole book-running manager for the offering. JMP
Securities LLC is acting as lead manager for the offering. Minerva intends to
grant the underwriters a 30-day option to purchase additional shares of its
common stock in an amount up to 15% of the shares sold in the offering, on the
same terms and conditions.
Minerva intends to use the net proceeds from the offering, together with its
existing cash and investments, to fund part of the continued clinical
development of MIN-101, MIN-117, MIN-202 and MIN-301, and for working capital
and general corporate purposes.
The securities described above are being offered pursuant to a shelf
registration statement on Form S-3 (File No. 333-205764) that was filed with the
United States Securities and Exchange Commission ("SEC") on July 21, 2015 and
that was declared effective by the SEC on July 27, 2015. The offering can be
made only by means of a written prospectus and prospectus supplement that form a
part of the registration statement. A preliminary prospectus supplement and
accompanying prospectus relating to the offering has been filed with the SEC and
is available on the SEC's website at www.sec.gov. Copies of the preliminary
prospectus supplement and the accompanying prospectus may also be obtained by
request at Jefferies LLC, Attention: Equity Syndicate Prospectus Department,
520 Madison Avenue, 2nd Floor, New York, NY 10022, telephone: (877) 821-7388, e-
mail: Prospectus_Department(at)Jefferies.com.
The securities described above have not been qualified under any state blue sky
laws. This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there be any sale of
these securities in any state or other jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of any such state or other jurisdiction.
About Minerva Neurosciences
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company
focused on the development and commercialization of a portfolio of products to
treat CNS diseases. Minerva's proprietary compounds include: MIN-101, which has
completed Phase IIb development for schizophrenia; MIN-202 (JNJ-42847922), which
has completed Phase IIa and Phase Ib clinical trials in insomnia and MDD,
respectively; MIN-117, which has completed Phase IIa development for MDD; and
MIN-301, in pre-clinical development for Parkinson's disease. Minerva's common
stock is listed on the NASDAQ Global Market under the symbol "NERV."
Forward-Looking Statements
Any statements in this press release about future expectations, plans and
prospects for Minerva Neurosciences, Inc., including statements about Minerva's
anticipated public offering, anticipated use of proceeds and plans and prospects
for Minerva and other statements containing the words "anticipate," "believe,"
"estimate," "expect," "intend," "may," "plan," "predict," "project," "target,"
"potential," "will," "would," "could," "should," "continue," and similar
expressions, constitute forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995. Actual results may differ
materially from those indicated by such forward-looking statements as a result
of various important factors, including: the uncertainties related to market
conditions and the completion of the public offering on the anticipated terms or
at all, uncertainties inherent in the initiation of future clinical trials and
such other factors as are set forth in the risk factors detailed in Minerva's
Quarterly Report on Form 10-Q filed with the SEC on May 3, 2016 under the
heading "Risk Factors." In addition, the forward-looking statements included in
this press release represent Minerva's views as of the date hereof. Minerva
anticipates that subsequent events and developments will cause Minerva's views
to change. However, while Minerva may elect to update these forward-looking
statements at some point in the future, Minerva specifically disclaims any
obligation to do so. These forward-looking statements should not be relied upon
as representing Minerva's views as of any date subsequent to the date hereof.
William B. Boni
VP, Investor Relations/
Corp. Communications
Minerva Neurosciences, Inc.
(617) 600-7376
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Minerva Neurosciences, Inc. via GlobeNewswire
[HUG#2020274]
Datum: 13.06.2016 - 22:01 Uhr
Sprache: Deutsch
News-ID 477410
Anzahl Zeichen: 5975
contact information:
Town:
Waltham
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 207 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Minerva Neurosciences Announces Proposed Public Offering of Common Stock"
steht unter der journalistisch-redaktionellen Verantwortung von
Minerva Neurosciences, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
